echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Chengdu Beite's 3 major new products will be approved

    Chengdu Beite's 3 major new products will be approved

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Chengdu Better (including its subsidiaries) has 3 new generic drugs that have been classified for production and entered the administrative approval stage, namely Futhiaxetine Hydrobromide Tablets, Lenvatinib Mesylate Capsules and Ipratropium Bromide.


    Source: official website of the State Drug Administration

    Lenvatinib is a multi-target receptor tyrosine kinase inhibitor developed by Eisai.


    The original research product was approved to enter the domestic market in September 2018, breaking the long-term monopoly of sorafenib in the first-line liver cancer market.


    The lenvatinib mesylate capsules of Zhengda Tianqing and Simcere Pharmaceuticals were approved for the market on the same day, and they were tied for the first imitation; the products of Nanjing Zhengda Tianqing and Qilu Pharmaceuticals were also approved one after another, and Chengdu Beite’s products entered "Under approval" status, is expected to win the fifth domestically produced company


    Source: official website of the State Drug Administration

    Futhiaxetine is a serotonin (5-HT) reuptake inhibitor developed by Lingbei.


    At present, 7 domestic companies have submitted applications for the listing of vothiaxetine hydrobromide tablets.


    Source: official website of the State Drug Administration

    Ipratropium bromide is a highly selective M receptor blocker, which is suitable for the relief of chronic asthmatic bronchitis


    In addition to the original research products, currently only the two companies of China Resources Double Crane and Beijing Hyderun are on the market for ipratropium bromide aerosol, and Sichuan Prime (a subsidiary of Bettertech) is expected to become the third domestic company


    Source: Mi Nei.


    Note: The statistics are as of October 26.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.